Lodo Therapeutics

Lodo Therapeutics

Lodo Therapeutics was established as a single-family office with a focus on discovering novel therapeutics from microbial natural products. The founding family has not publicly disclosed the wealth origin, but the firm operates from offices in New Brunswick, New York, and Seattle. The investment strategy targets early-stage biotech and pharmaceutical opportunities, with a particular emphasis on machine-learning-driven drug discovery. Lodo's approach integrates genomics, cheminformatics, and synthetic biology to identify and characterize natural product leads. Direct investments have been made into platform companies that advance these technologies. The portfolio spans preclinical and clinical-stage assets, with a geographic focus on North American and European biotech hubs. The firm maintains a lean team and does not disclose AUM or total deployment. Lodo may also operate adjacent philanthropic or research vehicles, though these are not publicly detailed. One recent operational event: Lodo Therapeutics was acquired by Ginkgo Bioworks in 2022, integrating its discovery platform into Ginkgo's autonomous lab infrastructure. A key structural differentiator is Lodo's focus on natural product biosynthesis as a source of new drug leads, an area often overlooked by big pharma. The firm's tight integration with Ginkgo Bioworks post-acquisition provides access to high-throughput screening and synthetic biology capabilities, creating a unique hybrid of family office capital and public company R&D infrastructure.